Vebreltinib is a synthetic small-molecule anticancer compound and a selective c-Met (MET/HGFR) tyrosine kinase inhibitor. It is also known by the development names APL-101, PLB-1001, CBT-101, and Bozitinib. Vebreltinib has been developed as an orally bioavailable, ATP-competitive type 1b MET inhibitor and has been investigated for cancers associated with MET alterations.
Vebreltinib has the molecular formula C20H15F3N8 and a molecular weight of approximately 424.39 g/mol. Its CAS Registry Number is 1440964-89-5, and its FDA Unique Ingredient Identifier (UNII) is 2WZP8A9VFN. The compound is achiral and has no defined stereocenters.
The mechanism of action of vebreltinib is associated with selective inhibition of the MET receptor tyrosine kinase. MET, also known as hepatocyte growth factor receptor (HGFR), is involved in signaling pathways regulating cell proliferation, survival, migration, invasion, and other cellular processes. Aberrant MET signaling can occur through amplification, mutation, fusion, or other dysregulation. Vebreltinib binds to the ATP-binding region of the MET kinase and inhibits MET phosphorylation and downstream signaling.
Vebreltinib has been investigated particularly in non-small-cell lung cancer (NSCLC) with MET alterations, including MET exon 14 skipping and MET amplification. Clinical development has also evaluated its potential application in other solid tumors with MET dysregulation. The compound has demonstrated activity against wild-type MET and selected MET variants in biochemical and cellular studies.
From a pharmaceutical manufacturing perspective, Vebreltinib is a chemically defined small molecule rather than a biological product. Its manufacturing and quality-control program therefore involves characterization of chemical identity, assay/purity, related substances, residual solvents, water content, elemental impurities, and other applicable physicochemical parameters. However, publicly accessible information does not establish a universal current USP or Ph. Eur. API monograph with numerical acceptance limits for all of these parameters. Consequently, numerical release specifications for fields such as loss on drying, residue on ignition, individual impurities, total impurities, and water should be based on the applicable approved or validated product specification rather than assumed generic limits.
Vebreltinib is relevant to pharmaceutical research and development involving targeted oncology therapies and MET-directed treatment strategies. Its chemical structure incorporates fluorinated heterocyclic systems, including a triazolopyridazine core and substituted pyrazole and indazole groups. The compound's systematic chemical name is 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine.
Vebreltinib API can be considered for pharmaceutical development, analytical research, reference-standard activities, and formulation development where legally and technically appropriate. A pharmaceutical manufacturer and supplier in India handling Vebreltinib should maintain appropriate controls for identity, assay, purity, impurities, residual solvents, water, and other quality attributes applicable to the intended grade and regulatory market.
For commercial API development, quality documentation may include analytical specifications, certificate of analysis, analytical methods, impurity profiles, residual-solvent data, stability information, and other technical documentation depending on customer and regulatory requirements. Because publicly available sources do not provide a complete universal pharmaceutical API specification for Vebreltinib, the final release specification should be established according to the applicable regulatory dossier and validated manufacturing process.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.20% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.50% |
| Total Impurities | NMT 1.50% |
| Water Content | NMT 1.0% |